Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $74.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 24.22% year-over-year to $74.1 million, compared with a TTM value of $74.1 million through Sep 2025, down 24.22%, and an annual FY2024 reading of $91.5 million, down 17.01% over the prior year.
  • Non-Current Deffered Revenue was $74.1 million for Q3 2025 at Bicycle Therapeutics, down from $82.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $115.1 million in Q2 2023 and bottomed at $25.3 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $71.7 million, with a median of $82.2 million recorded in 2025.
  • The sharpest move saw Non-Current Deffered Revenue surged 165.87% in 2023, then decreased 24.22% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $52.1 million in 2021, then dropped by 20.38% to $41.5 million in 2022, then surged by 165.87% to $110.2 million in 2023, then dropped by 17.01% to $91.5 million in 2024, then fell by 18.97% to $74.1 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for BCYC at $74.1 million in Q3 2025, $82.9 million in Q2 2025, and $82.2 million in Q1 2025.